Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to enterobacteriaceae producing extended-spectrum β-lactamases: A systematic review and meta-analysis

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 12, 2012, Pages 2793-2803

  Vardakas, Konstantinos Z ^a,b   Tansarli, Giannoula S ^a   Rafailidis, Petros I ^a,b   Falagas, Matthew E ^a,b,c  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b HENRY DUNANT HOSPITAL   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Enterobacter; ESBLs; Escherichia; Gram negative; Klebsiella; Mortality; Proteus

Indexed keywords

BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEPHALOSPORIN; EXTENDED SPECTRUM BETA LACTAMASE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ARTICLE; BACTEREMIA; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; HEALTHCARE ASSOCIATED INFECTION; HUMAN; KLEBSIELLA PNEUMONIAE; MEDLINE; META ANALYSIS; MONOTHERAPY; MORTALITY; NONHUMAN; SYSTEMATIC REVIEW;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CARBAPENEMS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84869484115     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks301     Document Type: Article

References (51)

1. Falagas ME, Karageorgopoulos DE. Extended-spectrum β-lactamaseproducing organisms. J Hosp Infect 2009; 73: 345-54.
2. Pitout JD. Infections with extended-spectrum β-lactamase-producing Enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs 2010; 70: 313-33.
3. Pitout JD, Laupland KB. Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008; 8: 159-66.
4. Ramphal R, Ambrose PG. Extended-spectrum β-lactamases and clinical outcomes: current data. Clin Infect Dis 2006; 42 Suppl 4: S164-72.
5. Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev 2005; 18: 657-86.
6. Ben-Ami R, Schwaber MJ, Navon-Venezia S et al. Influx of extended-spectrum β-lactamase-producing Enterobacteriaceae into the hospital. Clin Infect Dis 2006; 42: 925-34.
7. Rodriguez-Bano J, Alcala JC, Cisneros JM et al. Community infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Arch Intern Med 2008; 168: 1897-902.
8. Falagas ME, Rafailidis PI, Kofteridis D et al. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study. J Antimicrob Chemother 2007; 60: 1124-30.
9. Kim YK, Pai H, Lee HJ et al. Bloodstream infections by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother 2002; 46: 1481-91.
10. Paterson DL. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum blactamases (ESBLs). Clin Microbiol Infect 2000; 6: 460-3.
11. Paterson DL, Mulazimoglu L, Casellas JM et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum β-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 2000; 30: 473-8.
12. Garau J. Other antimicrobials of interest in the era of extendedspectrum β-lactamases: fosfomycin, nitrofurantoin and tigecycline. Clin Microbiol Infect 2008; 14 Suppl 1: 198-202.
13. Graffunder EM, Preston KE, Evans AM et al. Risk factors associated with extended-spectrum β-lactamase-producing organisms at a tertiary care hospital. J Antimicrob Chemother 2005; 56: 139-45.
14. Rodriguez-Bano J, Navarro MD, Retamar P et al. β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 2012; 54: 167-74.
15. Bellissimo-Rodrigues F, Gomes AC, Passos AD et al. Clinical outcome and risk factors related to extended-spectrum β-lactamase-producing Klebsiella spp. infection among hospitalized patients. Mem Inst Oswaldo Cruz 2006; 101: 415-21.
16. Chung HC, Lai CH, Lin JN et al. Bacteremia caused by extended-spectrum-β-lactamase-producing Escherichia coli sequence type ST131 and non-ST131 clones: comparison of demographic data, clinical features, and mortality. Antimicrob Agents Chemother 2012; 56: 618-22.
17. Tuon FF, Bianchet LC, Penteado-Filho SR. Epidemiology of extended spectrum β-lactamase producing Enterobacter bacteremia in a Brazilian hospital. Rev Soc Bras Med Trop 2010; 43: 452-4.
18. Tuon FF, Kruger M, Terreri M et al. Klebsiella ESBL bacteremia- mortality and risk factors. Braz J Infect Dis 2011; 15: 594-8.
19. Apisarnthanarak A, Kiratisin P, Mundy LM. Predictors of mortality from community-onset bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2008; 29: 671-4.
20. Velaphi S, Wadula J, Nakwa F. Mortality rate in neonates infected with extended-spectrum β-lactamase-producing Klebsiella species and selective empirical use of meropenem. Ann Trop Paediatr 2009; 29: 101-10.
21. Bin C, Hui W, Renyuan Z et al. Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum β-lactamaseproducing Escherichia coli. Diagn Microbiol Infect Dis 2006; 56: 351-7.
22. Chaubey VP, Pitout JD, Dalton B et al. Clinical outcome of empiric antimicrobial therapy of bacteremia due to extended-spectrum β-lactamase producing Escherichia coli and Klebsiella pneumoniae. BMC Res Notes 2010; 3: 116.
23. De Rosa FG, Pagani N, Fossati L et al. The effect of inappropriate therapy on bacteremia by ESBL-producing bacteria. Infection 2011; 39: 555-61.
24. Du B, Long Y, Liu H et al. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome. Intensive Care Med 2002; 28: 1718-23.
25. Endimiani A, Luzzaro F, Brigante G et al. Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum β-lactamases. Antimicrob Agents Chemother 2005; 49: 2598-605.
26. Ferrandez O, Grau S, Saballs P et al. [Mortality risk factors for bloodstream infections caused by extended-spectrum β-lactamaseproducing microorganisms.] Rev Clin Esp 2011; 211: 119-26.
27. Gudiol C, Calatayud L, Garcia-Vidal C et al. Bacteraemia due to extended-spectrum β-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother 2010; 65: 333-41.
28. Kang CI, Kim SH, Park WB et al. Bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 2004; 48: 4574-81.
29. Kang CI, Park SY, Chung DR et al. Piperacillin-tazobactam as an initial empirical therapy of bacteremia caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. J Infect 2012; 64: 533-4.
30. Lee CC, Lee NY, Yan JJ et al. Bacteremia due to extended-spectrum-blactamase-producing Enterobacter cloacae: role of carbapenem therapy. Antimicrob Agents Chemother 2010; 54: 3551-6.
31. Lee CH, Su LH, Tang YF et al. Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates. J Antimicrob Chemother 2006; 58: 1074-7.
32. Metan G, Altinbas A, Zarakolu P et al. Predictors of mortality in patients with bacteremia of unknown source due to extended spectrum β-lactamase producing Escherichia coli. J Chemother 2009; 21: 448-51.
33. Paterson DL, Ko WC, Von Gottberg A et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum β-lactamases. Clin Infect Dis 2004; 39: 31-7.
34. Qureshi ZA, Paterson DL, Pakstis DL et al. Risk factors and outcome of extended-spectrum β-lactamase-producing Enterobacter cloacae bloodstream infections. Int J Antimicrob Agents 2011; 37: 26-32.
35. Tumbarello M, Sanguinetti M, Montuori E et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-blactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 2007; 51: 1987-94.
36. Rodriguez-Bano J, Navarro MD, Romero L et al. Bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 2006; 43: 1407-14.
37. Rodriguez-Bano J, Picon E, Gijon P et al. Community-onset bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis 2010; 50: 40-8.
38. Chen YH, Hsueh PR, Badal RE et al. Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria. J Infect 2011; 62: 280-91.
39. Hawser S, Hoban D, Bouchillon S et al. Antimicrobial susceptibility of intra-abdominal gram-negative bacilli from Europe: SMART Europe 2008. Eur J Clin Microbiol Infect Dis 2011; 30: 173-9.
40. Hoban DJ, Bouchillon SK, Hawser SP et al. Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother 2010; 54: 3031-4.
41. Unal S, Masterton R, Goossens H. Bacteraemia in Europe- antimicrobial susceptibility data from the MYSTIC surveillance programme. Int J Antimicrob Agents 2004; 23: 155-63.
42. Siempos II, Ioannidou E, Falagas ME. The difference between adequate and appropriate antimicrobial treatment. Clin Infect Dis 2008; 46: 642-4.
43. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Testing: Twenty-first Informational Supplement M100-S21. CLSI, Wayne, PA, USA, 2011.
44. Paterson DL, Ko WC, Von Gottberg A et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39: 2206-12.
45. Jones RN, Pfaller MA. Antimicrobial activity against strains of Escherichia coli and Klebsiella spp. with resistance phenotypes consistent with an extended-spectrum β-lactamase in Europe. Clin Microbiol Infect 2003; 9: 708-12.
46. Martinez JA, Cobos-Trigueros N, Soriano A et al. Influence of empiric therapy with a β-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to Gram-negative microorganisms. Antimicrob Agents Chemother 2010; 54: 3590-6.
47. Nakamura T, Komatsu M. [Susceptibility of ESBL-producing Escherichia coli and Klebsiella pneumoniae to various antibacterial agents.] Jpn J Antibiot 2005; 58: 1-10.
48. Nakamura T, Shimizu C, Kasahara M et al. Monte Carlo simulation for evaluation of the efficacy of carbapenems and new quinolones against ESBL-producing Escherichia coli. J Infect Chemother 2009; 15: 13-7.
49. Raveh D, Yinnon AM, Broide E et al. Susceptibilities of ESBL-producing Enterobacteriaceae to ertapenem, meropenem and piperacillin-tazobactam with and without clavulanic acid. Chemotherapy 2007; 53: 185-9.
50. Turner PJ. MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates. Diagn Microbiol Infect Dis 2009; 63: 217-22.
51. Sterne JAC, Egger M, Moher D. Detecting reporting biases. In: Higgins PT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration and John Wiley & Sons Ltd, 2009.